iRadimed Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Roger Susi
- Full Time Employees
- 166
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1025 Willa Springs Drive Orlando FL United States 32826
- IPO Date
- Jul 15, 2014
- CIK
- 0001325618
- Website
- iradimed.com
- Similar Companies
- Business
- IRadimed Corporation IRadimed Corporation (NASDAQ: IRMD) develops, manufactures, markets and distributes magnetic resonance imaging (MRI)-compatible medical devices, accessories, disposables and related services to hospitals, acute care facilities and endoscopy centers in the United States and internationally. The company offers the MRidium series of non-magnetic MRI IV infusion pump systems, including the MRidium 3860+ for continuous medication delivery during MRI procedures, the newly FDA-cleared MRidium 3870 next-generation infusion pump with enhanced touchscreen interface, graphical user interface, advanced safety features and multi-channel capabilities for critical care patients, and the 3880 MRI-compatible patient vital signs monitoring system featuring wireless ECG, SpO2, respiratory CO2, blood pressure and optional multi-gas anesthetic agent monitoring operable in magnetic fields up to 30,000 gauss; the FMD Smart MRI ferrous metal detector with TruSense threat qualification technology to reduce false alarms; proprietary disposable IV tubing sets; and associated maintenance and support services. Founded in 1992 and headquartered in Orlando, Florida, IRadimed Corporation maintains a leading market position as the sole provider of non-magnetic MRI infusion pumps and monitors, with operations focused on the medical devices sector serving high-acuity patients including those in ICU, anesthesia and pediatric care requiring uninterrupted monitoring and fluid delivery. Recent developments include FDA 510(k) clearance for the MRidium 3870 infusion pump system in May 2025, with limited commercial shipments commencing in December 2025 and full U.S. rollout in the first quarter of 2026; relocation to a new facility in Orlando amid transitional operational challenges; record Q3 2025 revenue of $21.2 million, a raised full-year revenue guidance to $82.5 million-$83.5 million, and a quarterly cash dividend declaration of $0.17 per share payable November 25, 2025; and participation in investor conferences such as the 2025 Wells Fargo Healthcare Conference.
Company News
What iRadimed (IRMD) Said on Its Q3 Earnings Call
IRADIMED CORPORATION (IRMD) Q3 2026 Earnings Call Transcript
IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
Riverwater Small Cap Strategy Q3 2026 Portfolio Update
iRadimed (IRMD) Expected to Post Earnings on Friday
IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Head-To-Head Contrast: iRadimed (NASDAQ:IRMD) & Medline (NASDAQ:MDLN)
iRadimed Corp (IRMD) Stock Down 3.8% but Still Overvalued -- GF Score: 92/100
Algert Global LLC Sells 15,062 Shares of iRadimed Corporation $IRMD
iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of “Moderate Buy” by Brokerages
iRadimed Q2 Earnings Call Highlights
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Why Iradimed Stock Topped the Market Today
iRadimed Corp (IRMD) Shares Surge 4.4% -- What GF Score of 95 Tells Investors
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript